These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 36279864

  • 1. [Use of antifibrotic drugs in interstitial lung disease].
    Kreutz CP, Gesierich W, Behr J, Kneidinger N.
    Dtsch Med Wochenschr; 2022 Oct; 147(21):1383-1390. PubMed ID: 36279864
    [Abstract] [Full Text] [Related]

  • 2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN.
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [Abstract] [Full Text] [Related]

  • 3. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE, Kahn N, Wälscher J, Sarmand N, Polke M, Lars K, Eichinger M, Heussel CP, Palmucci S, Sambataro FM, Sambataro G, Sambataro D, Vancheri C, Kreuter M.
    BMC Pulm Med; 2019 Nov 12; 19(1):213. PubMed ID: 31718637
    [Abstract] [Full Text] [Related]

  • 4. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S.
    Mod Rheumatol; 2021 Jan 12; 31(1):13-19. PubMed ID: 32964766
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Advances with pharmacotherapy for the treatment of interstitial lung disease.
    Comes A, Sgalla G, Perrotta A, Richeldi L.
    Expert Opin Pharmacother; 2022 Mar 12; 23(4):483-495. PubMed ID: 34907821
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
    Joannes A, Voisin T, Morzadec C, Letellier A, Gutierrez FL, Chiforeanu DC, Le Naoures C, Guillot S, De Latour BR, Rouze S, Jaillet M, Crestani B, Wollin L, Jouneau S, Vernhet L.
    Pulm Pharmacol Ther; 2023 Dec 12; 83():102267. PubMed ID: 37972706
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework.
    Langford B, Diamantopoulos A, Maher TM, Inoue Y, Rohr KB, Baldwin M.
    Adv Ther; 2022 Feb 12; 39(2):1045-1054. PubMed ID: 34957531
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
    Richeldi L, Varone F, Bergna M, de Andrade J, Falk J, Hallowell R, Jouneau S, Kondoh Y, Morrow L, Randerath W, Strek M, Tabaj G.
    Eur Respir Rev; 2018 Dec 31; 27(150):. PubMed ID: 30578333
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
    Joung KI, Park H, Park S, Shin JY, Kim YH.
    BMC Pulm Med; 2023 Mar 22; 23(1):98. PubMed ID: 36949407
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.